pI: 10.5738 |
Length (AA): 469 |
MW (Da): 53347 |
Paralog Number:
0
Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
132 | 208 | 1gqe (A) | 237 | 337 | 36.00 | 0.052 | 0.46 | 0.225979 | 0.25 |
203 | 333 | 4ilo (A) | 20 | 152 | 13.00 | 0.085 | 0.02 | 0.390318 | -0.17 |
417 | 461 | 3brc (A) | 23 | 66 | 36.00 | 0.82 | 0.07 | 0.407749 | 0.26 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_129206)
Species | Accession | Gene Product |
---|---|---|
Babesia bovis | BBOV_IV005260 | conserved hypothetical protein |
Brugia malayi | Bm1_08890 | hypothetical protein |
Candida albicans | CaO19.5488 | similar to S. cerevisiae YLR281C |
Candida albicans | CaO19.12943 | similar to S. cerevisiae YLR281C |
Caenorhabditis elegans | CELE_T23B5.4 | Protein T23B5.4, isoform B |
Drosophila melanogaster | Dmel_CG30100 | CG30100 gene product from transcript CG30100-RA |
Echinococcus granulosus | EgrG_000185900 | peptide chain release factor corf |
Echinococcus multilocularis | EmuJ_000185900 | peptide chain release factor corf mitochondrial polypeptide chain release factor |
Homo sapiens | ENSG00000130921 | chromosome 12 open reading frame 65 |
Leishmania braziliensis | LbrM.30.3570 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_303600.1 | RF-1 domain containing protein, putative |
Leishmania infantum | LinJ.30.3600 | hypothetical protein, conserved |
Leishmania major | LmjF.30.3540 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.29.3540 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_08838 | hypothetical protein |
Mus musculus | ENSMUSG00000047635 | RIKEN cDNA 2810006K23 gene |
Onchocerca volvulus | OVOC3962 | Putative peptide chain release factor C12orf65, mitochondrial |
Plasmodium berghei | PBANKA_1007300 | peptide chain release factor 2, putative |
Plasmodium falciparum | PF3D7_0409700 | peptide chain release factor 2 |
Plasmodium knowlesi | PKNH_0307800 | peptide chain release factor 2, putative |
Plasmodium vivax | PVX_000760 | hypothetical protein, conserved |
Plasmodium yoelii | PY04089 | hypothetical protein |
Saccharomyces cerevisiae | YLR281C | hypothetical protein |
Schistosoma japonicum | Sjp_0213390 | similar to Uncharacterized protein C12orf65, putative |
Schistosoma mansoni | Smp_079810 | hypothetical protein |
Schmidtea mediterranea | mk4.000724.04 | Probable peptide chain release factor C12orf65, mitochondrial |
Trypanosoma brucei gambiense | Tbg972.6.4740 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.6.4940 | RF-1 domain containing protein, putative |
Trypanosoma congolense | TcIL3000_6_4360 | RF-1 domain containing protein, putative |
Trypanosoma cruzi | TcCLB.506945.180 | RF-1 domain containing protein, putative |
Toxoplasma gondii | TGME49_206360 | peptidyl-tRNA hydrolase domain-containing protein |
Theileria parva | TP01_0213 | hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.4940 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.4940 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.4940 this record | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.6.4940 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1007300 | Plasmodium berghei | Dispensable | plasmo |
TGME49_206360 | Toxoplasma gondii | Essentiality uncertain | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.